Synonyms: UCB 0107
Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Tau (timeline)
Condition(s): Progressive Supranuclear Palsy
U.S. FDA Status: Progressive Supranuclear Palsy (Phase 1)
Company: UCB S.A.
This monoclonal antibody binds to the mid-region of tau, recognizing amino acids 235–246 near tau's microtubule-binding domain. The rationale of this approach is that mid-region antibodies will more potently interfere with the cell-to-cell propagation of pathogenic, aggregated tau than do N-terminally targeted anti-tau antibodies. UCB1017 was reported to inhibit seeding in cellular assay and inhibit spread of tau pathology in a mouse model (Apr 2018 conference news). UCB1017 also binds tau monomers.
In February 2018, Brussels-based UCB Biopharma started a first single-ascending-dose study, evaluating the safety and tolerability of UCB0107 intravenous infusion. The double-blind, placebo-controlled trial will enroll 52 healthy men, and use up to seven dose groups depending on safety review of the previous, lower dose. Besides adverse events, the 20-week trial will measure UCB0107 exposure in blood and CSF, pharmacokinetic parameters of antibody distribution and clearance, as well as presence of anti-UCB0107 host antibodies. The trial is expected to end in November 2018.
For registry information on this antibody, see clinicaltrials.gov.
No Available Further Reading